Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
CASE REPORT
Tocilizumab in refractory adult-onset Still’s disease – case report and review of the literature
Online publication date: 2012-06-27
Reumatologia 2012;50(3):238-242
KEYWORDS
ABSTRACT
Adult-onset Still’s disease (AOSD) is an uncommon systemic connective tissue disease, characterized by a typical spiking fever, evanescent rash, arthritis (Fig. 1, 2), hepatosplenomegaly, lymphadenopathy and sore throat. Non-steroidal anti-inflammatory drugs, corticosteroids and immunosuppressants are commonly used as therapeutic agents for AOSD, but some patients are refractory to these conventional therapies. A case of a young woman with severe polyarthritis, refractory to corticosteroids and methotrexate, but successfully treated with the humanized monoclonal anti IL-6 receptor antibody tocilizumab is presented.
REFERENCES (20)
1.
Puszczewicz M. Choroba Stilla u dorosłych. Reumatologia. Medical Tribune Polska, Warszawa 2010; 90, 92, 239-243.
3.
Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult-onset Still’s disease. Ann Rheum Dis 2006; 65: 564-572.
4.
Eisen A, Amital H. Adult Still disease. In: Diagnostic Criteria in autoimmune diseases. Shoenfeld Y, Cervene R, Gershvin E (ed.). Humana Press, Totowa 2008; 25-29.
5.
Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol 1992; 19: 424-430.
6.
Bagnari V, Colina M, Ciancio G, et al. Adult-onset Still’s disease. Rheumatol Int 2010; 30: 855-862.
7.
Sabnis GR, Gokhale YA, Kulkarni UP. Tocilizumab in refractory adult-onset Still’s disease with aseptic meningitis – efficacy of interleukin-6 blockade and review of the literature. Semin Arthritis Rheum 2010; 40: 365-368.
8.
Thonhofer R, Hiller M, Just H, et al. Treatment of refractory adult-onset Still’s disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 2011; 31: 1653-1656.
9.
Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol 2010; 29: 1191-1194.
10.
Puéchal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken) 2011; 63: 155-159.
11.
Kobayashi M, Takahashi Y, Yamashita H, et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011; 21: 92-96.
12.
Perdan-Pirkmajer K, Praprotnik S, Tomšiè M. A case of refractory adult-onset Still’s disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 2010; 29: 1465-1467.
13.
Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adult-onset Still’s disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis 2011; 70: 390-392.
14.
Nakahara H, Mima T, Yoshio-Hoshino N, et al. A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 2008; 19: 69-72.
15.
Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab. Clin Rheumatol 2009; 28: 485-487.
16.
Lahiri M, Teng GG. A case of refractory adult-onset Still’s disease treated with anakinra. Intern J Rheum Dis 2010; 13: 36-41.
17.
Kishida D, Okuda Y, Onishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 2011; 21: 215-218.
18.
Fliciński J, Prajs K, Brzosko M. Choroba Stilla u dorosłych. Reumatologia kliniczna. Wydawnictwo Pomorskiego Uniwersytetu Medycznego, Szczecin 2010; 79-84.
19.
Yoshihiro Y, Sakamoto M, Yokota K, et al. Tocilizumab improved both clinical and laboratory manifestations except for interleukin 18 in a case of multiple drug-resistant adult-onset Still’s disease. Intern Med 2011; 50: 1757-1760.
20.
Woodrick RS, Ruderman EM. Interleukin-6 inhibition: RA and beyond. Bull NYU Hosp Jt Dis 2011; 69: 225-229.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
